GSK agrees to pay $90 million to settle diabetes drug allegations
By
McKnight's Staff
Nov 19, 2012
GlaxoSmithKline will pay a $90 million settlement to 38 states that claimed it unlawfully promoted its diabetes treatment Avandia (rosiglitazone). The attorneys general of several states confirmed the...
